Nutex Health earnings release, August 6, 2026

Nutex Health Inc. (NUTX) · Form 8-K, Item 2.02 · Filed · SEC filing

NUTEX HEALTH REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

HOUSTON, TX − (PRNewswire) – AUGUST 6, 2026 – Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), today announced financial results for the three and six months ended June 30, 2026. Nutex Health is a physician-led, healthcare services and operations company with 27 hospital facilities in 12 states (hospital division), and a primary care-centric, risk-bearing physician network.

Financial highlights for the three months ended June 30, 2026:

• Net income attributable to Nutex Health increased to $65.8 million, or diluted EPS of $9.38, compared to a loss of $17.7 million, or diluted EPS of $(2.95), for the three months ended June 30, 2025.

• EBITDA attributable to Nutex Health was $94.1 million and Adjusted EBITDA attributable to Nutex Health was $90.0 million, compared to $(0.5) million and $71.6 million, respectively, for the three months ended June 30, 2025.

• Total visits at the Hospital Division increased 9.6% year over year to 49,962, while visits at same hospitals, which are hospitals that were opened by December 31, 2024, increased 6.3%.

• Net cash provided by operating activities was $34.2 million for the three months ended June 30, 2026 as compared to $27.3 million for the same period in 2025.

Financial highlights for the six months ended June 30, 2026:

• Net income attributable to Nutex Health increased to $112.6 million, or diluted EPS of $15.87, compared to $3.5 million, or diluted EPS of $0.55, for the six months ended June 30, 2025.

• EBITDA attributable to Nutex Health was $162.5 million and Adjusted EBITDA attributable to Nutex Health was $147.5 million, compared to $51.1 million and $144.4 million, respectively, for the six months ended June 30, 2025.

• Total visits at the Hospital Division increased 6.2% year over year to 99,704, while visits at same hospitals increased 3.4%.

• Net cash provided by operating activities was $109.7 million for the six months ended June 30, 2026 as compared to $78.2 million for the same period in 2025; and as of June 30, 2026, the Company had long-term debt, net of $31.1 million, slightly up from $29.2 million as of December 31, 2025.

Note: EBITDA and Adjusted EBITDA are non-GAAP financial metrics. A reconciliation of non-GAAP to GAAP measures is included below in this earnings release.

Total revenue decreased 6.3% to $427.2 million for the six months ended June 30, 2026 compared to $455.8 million for the same period in 2025, while revenue at same hospitals decreased 6.0%. Total revenue decreased 13.6% to $210.8 million for the three months ended June 30, 2026 compared to $244.0 million for the same period in 2025, while revenue at same hospitals, decreased 12.1%. Most of the revenue decrease in 2026 compared to 2025 is due to the positive results from the early stage improvement in the IDR process that were realized in the first half of 2025.

The Company has submitted between 50–60% of its claims through IDR; when an award determination is made, Nutex Health currently prevails in over 85% of those determinations and collects, on average, over 80% of the award amounts.

Total arbitration-related costs decreased for both the three and six months ended June 30, 2026, reflected as a $52.3 million reduction to contract services expense. The reduction was driven primarily by the favorable June 30, 2026 retroactive amendment to the Company’s agreement with HaloMD and the reduction in the CMS administrative fee. The HaloMD amendment transitioned certain fees to a pay-on-collected basis retroactive to our original contract date of May 1, 2024 and revised service fee terms for federal and state net settlement amounts obtained on or after July 1, 2026. The CMS administrative fee for the federal IDR process was decreased from $115 to $15 per party per dispute effective June 11, 2026. The cumulative impact from these two key changes directly reduced the contract services expenses for the second quarter and six months ended 2026 period by $52.3 million. Based on current expectations, we anticipate the impact of these favorable changes will lead to an approximate 25-30% reduction in our normalized historical contract services expenses prospectively. This impact is based on the current regulatory outlook and the Company's current expectations. Actual contract services expenses incurred in the future may differ significantly. One additional item within the HaloMD agreement is that the Company may perform dispute resolution services in-house or through the engagement of another third-party vendor or service provider with respect to certain future facilities.

Total stock-based compensation for the six months ended June 30, 2026 was a gain of $1.0 million, compared to an expense of $106.4 million for the same period in 2025. Net income attributable to Nutex Health increased 3100% in the first six months of 2026 as compared to the same period in 2025, underscoring strong operating cash generation and execution of its planned growth strategy.¹

“2026 is continuing to be a solid financial year, including total revenue of $427.2 million, net income attributable to Nutex of $112.6 million, diluted EPS of $15.87 per share and $109.7 million of operating cash flow in the first six months of 2026. We also delivered meaningful operating income improvement, with operating income increasing to $203.0 million for the first six months of 2026 from $114.3 million in the same period of 2025, supported by lower total operating costs and expenses of $194.2 million compared to $212.5 million in the prior-year period. Our balance sheet remains strong with a cash balance of $205.2 million and long-term debt of $31.1 million. We believe we are set up well for finishing the year strong as we continue to grow with the expected opening of three new hospital later this year,” stated Jon Bates, Chief Financial Officer of Nutex Health.... (truncated)continue to execute on initiatives designed to strengthen internal processes and initiatives, expand patient access, and drive both patient volumes and inpatient admissions. Our operating performance, revenue cycle management execution, new hospital openings and disciplined expense management all contributed to improved profitability, including net income attributable to Nutex Health of $112.6 million and diluted EPS of $15.87 for the first six months of 2026," stated Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health.

For more details on the Company’s financial results for the three and six months ended June 30, 2026, please refer to our Quarterly Report on Form 10-Q filed with the U.S. Securities & Exchange Commission and accessible at www.sec.gov.

Conference Call on Second Quarter 2026 Results

The Company will host a conference call on Friday, August 7, 2026 at 9:30 a.m. CT to discuss its results for the first two quarters of 2026.

Participant Listening: 1-877-407-9208 or 1-201-493-6784

Participant Link: https://callme.viavid.com/viavid/?callme=true&passcode=13746493&h=true&info=company&r=true&B=6

To access the call, please dial in approximately five minutes before start time. Those who are unable to attend the live conference call may access the recording on the Company's website.²

Financial statements

Income Statement

Three Months Ended June 30, — CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (In thousands, except per share amounts)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Hospital division201,852236,302409,422440,249
Population health management division8,9007,68317,81515,525
Total revenue210,752243,985427,237455,774
Operating costs and expenses:Payroll42,75136,28484,19071,144
Operating costs and expenses:Contract services1,08261,10961,61499,764
Operating costs and expenses:Medical supplies5,3424,8129,3518,613
Operating costs and expenses:Depreciation and amortization5,3175,24810,80910,340
Operating costs and expenses:Other14,98111,60828,26422,651
Operating costs and expenses:Total operating costs and expenses69,473119,061194,228212,512
Operating costs and expenses:Gross profit141,279124,924233,009243,262
Corporate and other costs:Stock-based compensation2,88478,747-1,031106,389
Corporate and other costs:General and administrative expenses16,67712,49831,05722,533
Corporate and other costs:Total corporate and other costs19,56191,24530,026128,922
Corporate and other costs:Operating income121,71833,679202,983114,340
Corporate and other costs:Interest expense, net4,6715,6789,35311,798
Corporate and other costs:Other expense-384,269-157,594
Corporate and other costs:Income before taxes117,08523,732193,64594,948
Corporate and other costs:Income tax expense20,7687,58834,56527,998
Corporate and other costs:Net income96,31716,144159,08066,950
Corporate and other costs:Less: net income attributable to noncontrolling interests30,47533,84146,43163,430
Corporate and other costs:Net income attributable to Nutex Health Inc.65,842-17,697112,6493,520
Earnings per common share:Basic9.58-2.9516.260.6
Earnings per common share:Diluted9.38-2.9515.870.55

Income Statement

Three Months Ended June 30, (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025
Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA:Net income attributable to Nutex Health Inc.65,842-17,697
Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA:Depreciation and amortization5,3175,248
Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA:Interest expense, net4,6715,678
Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA:Income tax expense20,7687,588
Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA:Allocation to noncontrolling interests-2,452-1,275
Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA:EBITDA94,146-458
Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA:Stock-based compensation2,88478,747
Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA:Finance lease payments-7,045-6,675
Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA:Adjusted EBITDA89,98571,614

Income Statement

Six Months Ended June 30, (in thousands)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA:Net income attributable to Nutex Health Inc.112,6493,520
Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA:Depreciation and amortization10,80910,340
Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA:Interest expense, net9,35311,798
Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA:Income tax expense34,56527,998
Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA:Allocation to noncontrolling interests-4,925-2,572
Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA:EBITDA162,45151,084
Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA:Stock-based compensation-1,031106,389
Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA:Finance lease payments-13,871-13,038
Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA:Adjusted EBITDA147,549144,435

Balance Sheet

June 30, 2026 — CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (In thousands, except share and per share amounts)

June 30, 2026December 31, 2025
Cash and cash equivalents205,208185,574
Restricted cash1,900297
Accounts receivable351,675319,440
Accounts receivable - related parties5,0255,978
Inventories4,2072,866
Prepaid expenses and other current assets17,63524,656
Total current assets585,650538,811
Property and equipment, net (accumulated depreciation of 35,317 and 31,696 as of June 30, 2026 and December 31, 2025, respectively)95,70294,581
Operating lease right-of-use assets26,15026,955
Financing lease right-of-use assets219,067222,367
Intangible assets, net20,58021,230
Goodwill, net13,91913,919
Other assets3,561662
Total assets964,629918,525
Current liabilities:Accounts payable4,28145,863
Current liabilities:Accounts payable - related parties5,6793,104
Current liabilities:Lines of credit98740
Current liabilities:Current portion of long-term debt8,49613,336

Cash Flow

Six Months Ended June 30, — CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (in thousands)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net income159,08066,950
Adjustment to reconcile net income to net cash from operating activities:Depreciation and amortization10,80910,340
Adjustment to reconcile net income to net cash from operating activities:Stock-based compensation expense-1,031106,389
Adjustment to reconcile net income to net cash from operating activities:Changes to deferred taxes1,775-4,865
Adjustment to reconcile net income to net cash from operating activities:Debt accretion expense44504
Adjustment to reconcile net income to net cash from operating activities:Non-cash effect of change in estimate-52,319
Changes in operating assets and liabilities:(Increase)/Decrease in Accounts receivable-32,235-116,768
Changes in operating assets and liabilities:(Increase)/Decrease in Accounts receivable - related party953-2,135
Changes in operating assets and liabilities:(Increase)/Decrease in Inventories-1,341575
Changes in operating assets and liabilities:(Increase)/Decrease in Prepaid expenses and other current assets4,122-8,640
Changes in operating assets and liabilities:(Increase)/Decrease in Operating right-of-use assets805121
Changes in operating assets and liabilities:Increase/(Decrease) in Accounts payable-4,06719,334
Changes in operating assets and liabilities:Increase/(Decrease) in Accounts payable - related party2,5751,169
Changes in operating assets and liabilities:Increase/(Decrease) in Operating lease liabilities-728194
Changes in operating assets and liabilities:Increase/(Decrease) in Accrued arbitration expenses14,72921,043
Changes in operating assets and liabilities:Increase/(Decrease) in Accrued income tax expense3,139-18,169
Changes in operating assets and liabilities:Increase/(Decrease) in Accrued expenses and other current liabilities3,4082,180
Changes in operating assets and liabilities:Net cash provided by operating activities109,71878,222
Cash flows from investing activities:Acquisitions of property and equipment-3,741-815
Cash flows from investing activities:Proceeds from restricted short-term investment2,941
Cash flows from investing activities:Cash related to asset acquisition-1,994
Cash flows from investing activities:Net cash provided by (used in) investing activities-3,741132

Cash Flow

Six Months Ended June 30, — CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (in thousands)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Proceeds from lines of credit4,606
Proceeds from notes payable258
Repayments of lines of credit-642-301
Repayments of notes payable-2,953-5,697
Repayments of finance leases-3,317-2,593
Proceeds from exercise of warrants75
Cash related to stock repurchases and retirements-50,688
Members' contributions1,405242
Members' distributions-28,620-18,776
Net cash used in financing activities-84,740-22,261
Net change in cash, cash equivalents, and restricted cash21,23756,093
Cash and cash equivalents - beginning of the period185,57440,640
Restricted cash - beginning of period297
Cash and cash equivalents and restricted cash - beginning of period185,87140,640
Cash and cash equivalents - end of period205,20896,733
Restricted cash - end of period1,900
Cash and cash equivalents and restricted cash - end of period207,10896,733

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Nutex Health earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.